Abstract

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy and Safety Results of the Phase 3 Candor Study

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma
Steven M Horwitz ...
Blood | VOL. 136
Steven M Horwitz, et. al.Steven M Horwitz ...
05 Nov 2020
Effect of Age on the Efficacy and Safety of Single Agent Oral Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Pivotal Study
Michael W Schuster ...
Blood | VOL. 136
Michael W Schuster, et. al.Michael W Schuster ...
05 Nov 2020
One-Year Follow-up of ZUMA-2, the Multicenter, Registrational Study of KTE-X19 in Patients with Relapsed/Refractory Mantle Cell Lymphoma
Michael Wang ...
Blood | VOL. 136
Michael Wang, et. al.Michael Wang ...
05 Nov 2020
Sustained Minimal Residual Disease (MRD) Negativity and Clinical Efficacy in Transplant-Ineligible (TIE) Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Treated with Daratumumab-Based Regimens: Analysis of Maia and Alcyone
...
Blood | VOL. 136
, et. al. ...
05 Nov 2020
View more papers

More From: Blood

Paper Title
Journal
Date
Author
JAK2/mTOR Inhibition Fails to Prevent Acute GVHD Despite Reduced Th1/Th17 cells: Final Phase II Trial Results.
Joseph A Pidala ... Brian C Betts
Blood | VOL. -
Joseph A Pidala, et. al.Joseph A Pidala ... Brian C Betts
24 Jul 2024
Critical Role of Tripartite Fusion and LBD Truncation in Certain RARA- and all RARG-Related Atypical APL.
Xiaosu Zhou ... Hongxing Liu
Blood | VOL. -
Xiaosu Zhou, et. al.Xiaosu Zhou ... Hongxing Liu
24 Jul 2024
Ruxolitinib for pediatric patients with treatment-naïve and steroid-refractory acute graft-versus-host disease (REACH4).
Franco Locatelli ... Christina Diaz-De-Heredia
Blood | VOL. -
Franco Locatelli, et. al.Franco Locatelli ... Christina Diaz-De-Heredia
24 Jul 2024
A predictive model for therapy failure in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor therapy.
Xiaoshuai Zhang ... Qian Jiang
Blood | VOL. -
Xiaoshuai Zhang, et. al.Xiaoshuai Zhang ... Qian Jiang
24 Jul 2024
View more papers